Clinical Trial

SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-20.
Status change: Not Yet Recruiting → Recruiting 2026-03-25
Trial Details
NCT Number NCT07256236
Lead Sponsor Fujian Cancer Hospital
Conditions Cervical Cancer
Enrollment 89 participants
Start Date 2026-01-28
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-30